Arbiter Partners Capital Management LLC Invests $3.86 Million in Arvinas, Inc. $ARVN

Key Points

• Arbiter Partners bought 452,789 shares of Arvinas for roughly $3.86 million in Q3, making the holding about 2.3% of Arbiter’s portfolio and representing 0.71% ownership of Arvinas.
• Arvinas reported a sharp earnings miss on Feb. 24 (EPS -$1.10 vs. -$0.55 expected) and revenue of $9.5M vs. $37.3M est., a roughly 84% year‑over‑year decline; the stock trades near $13.76 with a market cap around $880M.
• Analyst views are mixed—10 Buys, 8 Holds and 2 Sells with an average target of $13.47—and insiders have recently sold shares (57,429 shares in the last 90 days), leaving insiders owning about 4.73% of the company.

Arbiter Partners Capital Management LLC purchased a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 452,789 shares of the company's stock, valued at approximately $3,858,000. Arvinas comprises about 2.3% of Arbiter Partners Capital Management LLC's investment portfolio, making the stock its 10th biggest position. Arbiter Partners Capital Management LLC owned 0.71% of Arvinas as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Rafferty Asset Management LLC bought a new stake in shares of Arvinas during the third quarter worth $115,000. Quantbot Technologies LP acquired a new stake in shares of Arvinas during the 3rd quarter valued at $338,000. Aster Capital Management DIFC Ltd bought a new stake in Arvinas during the 3rd quarter worth $92,000. Intech Investment Management LLC grew its position in Arvinas by 3.6% during the 3rd quarter. Intech Investment Management LLC now owns 32,653 shares of the company's stock worth $278,000 after acquiring an additional 1,125 shares during the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in Arvinas in the 3rd quarter worth about $504,000. Institutional investors own 95.19% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ARVN shares. Weiss Ratings restated a "sell (d-)" rating on shares of Arvinas in a report on Monday, December 22nd. Wall Street Zen lowered shares of Arvinas from a "hold" rating to a "sell" rating in a report on Monday. Barclays upped their price target on shares of Arvinas from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, December 17th. Wedbush raised their price target on shares of Arvinas from $9.00 to $11.00 and gave the company a "neutral" rating in a research note on Tuesday, February 24th. Finally, Citigroup raised shares of Arvinas from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $10.00 to $15.00 in a research note on Tuesday, January 6th. Ten research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $13.47.

Arvinas Stock Performance

Shares of ARVN stock opened at $13.76 on Thursday. Arvinas, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $18.93. The stock has a 50 day simple moving average of $12.56 and a two-hundred day simple moving average of $10.76. The company has a market cap of $880.09 million, a P/E ratio of -10.75 and a beta of 1.87.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.55). Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The company had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. During the same period last year, the business earned ($0.63) EPS. The business's quarterly revenue was down 84.0% compared to the same quarter last year. On average, research analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Insider Activity at Arvinas

In other Arvinas news, CEO Randy Teel sold 4,786 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $12.16, for a total value of $58,197.76. Following the transaction, the chief executive officer owned 149,696 shares in the company, valued at approximately $1,820,303.36. This represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John G. Houston sold 35,297 shares of the business's stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $13.21, for a total value of $466,273.37. Following the sale, the director owned 1,122,183 shares of the company's stock, valued at approximately $14,824,037.43. This represents a 3.05% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 57,429 shares of company stock valued at $731,014. 4.73% of the stock is currently owned by company insiders.

Arvinas Company Profile

Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.

The company's most advanced clinical candidates address hormone-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.